Mahmoud R Gaballa

8PUBLICATIONS
61CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsTe urupare me te whai wāhi Māori ki te mātauranga (Māori responsiveness and engaged education)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 23, 2026
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Nov 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Aimaz Afrough, Danai Dima, Beatrice Razzo

|Jun 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Danai Dima, Mariola A Vazquez-Martinez, James A Davis

|May 09, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Oren Pasvolsky, Danai Dima, Lei Feng

|Dec 27, 2024
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.

Mahmoud R Gaballa, Omar Castaneda Puglianini, Adam Cohen

Pageof 2

Frequent Collaborators

8 joint publications

Krina Patel

7 joint publications

Oren Pasvolsky

5 joint publications

Andrew Portuguese

5 joint publications

James A Davis